Post by
99942Apophis on Feb 18, 2022 5:04pm
Upcoming patient data
Our expectations of patient data in this upcoming Newsletter should contain results of patients 25 through to and include patient 30 for the period of 90 days.
Also we should receive data on patients 21, 22, 23 and 24 for their 180 period. This will give us a sense of future patients and their success going forward of which in my opinion will score very high.
Much talk lately whether we will hear any hint of other topics of interest as in partnership/partnerships, new patients, Ph1 of GBM & NSCLC and any advancement in the therapeutic/vaccine story! With recent changes in personal at the company my opinion is we will have better communication in both positive and negative information. Have a good long weekend.
Comment by
Oilminerdeluxe on Feb 19, 2022 6:53am
83 M market cap. I will never understand markets. It's getting really close to the next update. Should be a lot of data in it. Maybe we should change name to Theralase Crypto instead.
Comment by
StevenBirch on Feb 19, 2022 9:20am
I respectfully disagree Oil, we don't want to be some kind of fad that is vulnerable to big swings because those situations very seldom benefit investors like us. When the numbers come in and assuming they are as we expect they will speak for themselves and we will be rewarded.
Comment by
Oilminerdeluxe on Feb 19, 2022 9:57am
Oh , I was just venting som frustrations, StevenBirch :-) I hope Vera gives a few notes next time we here anything.
Comment by
StevenBirch on Feb 19, 2022 10:53am
Yes I know, me too but I think that's what the manipulators want! Most of us here don't act on that thank god because we are now looking at 5 days +/- before what could be the real launch of TLT. Let's see what Vera has for us beyond NMIBC.
Comment by
Oilminerdeluxe on Feb 19, 2022 11:05am
Fingers crossed. It would feel wonderful to climb closer to $1. Or at least past 50 cents. I don't know what it will take for the share price to take off if data so far has not done it. Perhaps we will simply have to wait for that BTD or perhaps some kind of beneficial j/v out of the blue. But solid data will of course make the wait a bit easier. Not long to go now.
Comment by
Eoganacht on Feb 19, 2022 3:46pm
So to outdo these results Theralase must maintain a greater than 39% CR rate after 18 months. (55% of 71%) Given the results so far that sounds very likely.
Comment by
greaterfoolFred on Feb 19, 2022 6:42pm
I have a question, but am too lazy to find out for myself, and I am sure that most of you already know the answer. Who are the patients being treated in the "N-803 + BCG for CIS disease" trial. Have these people already failed BCG treatment (like in our 1433 trial?) Or is this their first treament using BCG? Thanks, and good luck all.
Comment by
CancerSlayer on Feb 20, 2022 12:18am
Enrolled patients are BCG-unresponsive.... ClinicalTrials.gov Identifier: NCT03022825
Comment by
DJDawg on Feb 19, 2022 8:07pm
Hey Enrique. Do you find interesting the way the graph has several significant steps down right after the 24 m time point?
Comment by
Eoganacht on Feb 19, 2022 8:09pm
I think that's the correct interpretation. It's rather deceptive the way they express it. Merck did the same thing when they published the Keytruda results. They don't give the percentage CR of the entire trial population at different times - just the percentage of the original 72% CR who remained CR at 12 months and 18 months.
Comment by
enriquesuave on Feb 20, 2022 9:33am
It may also be that they don't have much data beyond the 24 months mark?
Comment by
CancerSlayer on Feb 20, 2022 9:46am
Yep...could be a small sample size at that point. But my guess is it is more than that...